1962年，畢業(yè)于北京醫(yī)學(xué)院；

1965年，北京協(xié)和醫(yī)學(xué)院研究生畢業(yè)；

1978年9月—1981年2月，赴法國(guó)國(guó)家腫瘤研究所進(jìn)修遺傳毒理學(xué)；

1986年9月—1987年7月，美國(guó)俄亥俄醫(yī)學(xué)院訪問學(xué)者；

1992年，荷蘭腫瘤研究所訪問學(xué)者；

1996年，MD Anderson Cancer Center訪問學(xué)者；

1992年—2001年，中國(guó)醫(yī)學(xué)科學(xué)院腫瘤研究所副所長(zhǎng)、腫瘤醫(yī)院副院長(zhǎng)；

1999年入選中國(guó)工程院院士 ^[1]  ；

1999年-2009年，國(guó)家重點(diǎn)基礎(chǔ)研究發(fā)展計(jì)劃“973”腫瘤項(xiàng)目首席科學(xué)家；

2003年-2012年，中國(guó)環(huán)境誘變劑學(xué)會(huì)理事長(zhǎng)；

2004年-2012年，中國(guó)抗癌協(xié)會(huì)副理事長(zhǎng) ^[3]  ；

2005年-2010年，北京市重大腫瘤專項(xiàng)的首席科學(xué)家；

2009年-2013年，衛(wèi)生部腫瘤行業(yè)專項(xiàng)首席專家；

2009年，獲何梁何利基金科學(xué)與技術(shù)進(jìn)步獎(jiǎng)；

2011年，獲北京協(xié)和醫(yī)學(xué)院“協(xié)和教學(xué)名師”稱號(hào)；

中國(guó)抗癌協(xié)會(huì)名譽(yù)副理事長(zhǎng) ^[3]  ；

第十屆全國(guó)政協(xié)委員；

程書鈞研究員從事腫瘤的化療病因和癌變機(jī)理研究毒理遺傳學(xué)研究30余年，主持國(guó)家七五、八五、九五、腫瘤攻關(guān)有關(guān)致癌物檢測(cè)及腫瘤早診課題。

建立了有先進(jìn)水平的致癌物快速檢測(cè)系統(tǒng)，對(duì)我國(guó)食管癌和肺癌發(fā)生相關(guān)的致癌因素作了大量研究并提供了重要資料。在抗致癌物研究中發(fā)現(xiàn)綠茶及其主要成分兒茶素可明顯抑制癌變及兒茶素對(duì)人的尖銳濕疣及炎癥增生有明顯治療作用，此項(xiàng)發(fā)明已獲國(guó)際專利，經(jīng)FDA批準(zhǔn)在美國(guó)進(jìn)行臨床試驗(yàn)，這是國(guó)際上首次FDA批準(zhǔn)的研究用天然兒茶素治療疾病，有重要的社會(huì)、經(jīng)濟(jì)效益和國(guó)際影響。

建立了適合我國(guó)應(yīng)用并有先進(jìn)水平的上皮細(xì)胞無(wú)血清培養(yǎng)技術(shù)，可用于培養(yǎng)多種人的上皮細(xì)胞。

首次建立四株中國(guó)人的永生化支氣管上皮細(xì)胞系并構(gòu)建了人肺癌變前病變模型。

提出以癌前病變發(fā)生與逆轉(zhuǎn)機(jī)理作為我國(guó)當(dāng)前腫瘤集注研究的主攻方向，已獲國(guó)家批準(zhǔn)，成為“國(guó)家重點(diǎn)基礎(chǔ)研究”首批入選項(xiàng)目，并擔(dān)任“惡性腫瘤發(fā)生與發(fā)展的基礎(chǔ)性研究”首席科學(xué)家。

多次獲衛(wèi)生部科技成果獎(jiǎng)及國(guó)家級(jí)榮譽(yù)獎(jiǎng)，對(duì)發(fā)展我國(guó)致癌物檢測(cè)和遺傳毒理學(xué)的研究作出了重要貢獻(xiàn)。 ^[1] 

程書鈞研究員學(xué)風(fēng)嚴(yán)謹(jǐn)，培養(yǎng)博士、碩士生23人，發(fā)表論著94篇，其中被美國(guó)SCI收錄的論文18篇，共被引用219次。

1990年被衛(wèi)生部授予全國(guó)衛(wèi)生系統(tǒng)優(yōu)秀留學(xué)回國(guó)人員稱號(hào)；

1991年被國(guó)家教委、人事部授予國(guó)家有突出貢獻(xiàn)留學(xué)回國(guó)人員；

1994年獲衛(wèi)生部有突出貢獻(xiàn)中青年專家。 ^[1] 

1 Shi X, Zhang Y, Cao B, Lu N, Feng L, Di X, Han N, Luo C, Wang G, Cheng S*, Zhang K*. Genes involved in the transition from normal epithelium to intraepithelial neoplasia are associated with colorectal cancer patient survival. Biochemical and Biophysical Research Communications 2013; 435(2):282-288.

2 Ling B, Zheng H, Fu G, Yuan J, Shi T, Chen S, Liu Y, Liu Y, Cao Y, Zheng S, Guo S, Han N, Gao Y, Cheng S*, Zhang K*. Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D. Lung cancer 2013; 79(2): 104-110.

3 Yang L, Rong W, Xiao T, Zhang Y, Xu B, Liu Y, Wang L, Wu F, Qi J, Zhao X, Wang H, Han N, Guo S, Wu J*, Gao Y*, Cheng S*. Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma. Sci China Life Sci. 2013 Jul;56(7):638-646. Li M, Ling B, Xiao T, Tan J, An N, Han N, Guo S, Cheng S, Zhang K. Sp1 transcriptionally regulates BRK1 expression in non-small cell lung cancer cells. Gene. 2014; 542 (2): 134-40.

4 Feng L, Wang J, Cao B, Zhang Y, Wu B, Di X, Jiang W, An N, Lu D, Gao S, Zhao Y, Chen Z, Mao Y, Gao Y, Zhou D, Jen J, Liu X, Zhang Y, Li X, Zhang K*, He J*, Cheng S*. Gene expression profiling in human lung development: an abundant resource for lung adenocarcinoma prognosis. PLoS One. 2014; 9(8): e105639.

5 Xu X, Liu Y, Zhou WX, Ma YC, Fei GJ, An N, Li Y, Wu X, Yao F, Cheng SJ, Feng L*, Lu XH*. Differential gene-expression profiling of gastric intraepithelial neoplasia and early-stage adenocarcinoma. World J Gastroenterol. 2014; In press.

6 An N, Shi X, Zhang Y, Lv N, Feng L, Di X, Han N, Wang G, Cheng S, Zhang K. Discovery of a Novel Immune Gene Signature with Profound Prognostic Value in Colorectal Cancer: A Model of Cooperativity Disorientation Created in the Process from Development to Cancer. PLoS One. 2015 Sep 1;10(9):e0137171.

7 Tong R, Feng L, Zhang L, Zhang J, Mao Y, Zhang K, Gao Y, Wang G, Cheng S. Decreased Interferon Alpha/Beta Signature Associated with Human Lung Tumorigenesis. J Interferon Cytokine Res. 2015 Aug 26.

8 Li F, Xiao Y, Huang F, Deng W, Zhao H, Shi X, Wang S, Yu X, Zhang L, Han Z, Luo L, Zhu Q, Jiang W, Cheng S, Li X, Zhang K. Spatiotemporal-specific lncRNAs in the brain, colon, liver and lung of macaque during development. Mol Biosyst. 2015 Oct 12.

9 An N, Yang X, Cheng S*, Wang G*, Zhang K*. Developmental genes significantly afflicted by aberrant promoter methylation and somatic mutation predict overall survival of late-stage colorectal cancer. Scientific Reports. 2015, 5:18616.

10 Feng L, Tong R, Liu X, Zhang K, Wang G, Zhang L, An N, Cheng S. A network-based method for identifying prognostic gene modules in lung squamous carcinoma. Oncotarget. 2016 Feb 23. doi: 10.18632/oncotarget.7632.

11 Yu X, Feng L, Liu D, Zhang L, Wu B, Jiang W, Han Z, Cheng S. Quantitative proteomics reveals the novel co-expression signatures in early brain development for prognosis of glioblastoma multiforme. Oncotarget. 2016 Feb 15. doi: 10.18632/oncotarget.7416

12 Zhang W, Bao L, Yang S, Qian Z, Dong M, Yin L, Zhao Q, Ge K, Deng Z, Zhang J, Qi F, An Z, Yu Y, Wang Q, Wu R, Fan F, Zhang L, Chen X, Na Y, Feng L, Liu L, Zhu Y, Qin T, Zhang S, Zhang Y, Zhang X, Wang J, Yi X, Zou L, Xin HW, Ditzel HJ, Gao H, Zhang K, Liu B, Cheng S. Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells. Oncotarget. 2016 May 18. doi: 10.18632/oncotarget.9465.

13 Yu X, Feng L, Han Z, Wu B, Wang S, Xiao Y, Li F, Zhang L, Cao B, Di X, Lu D, Li X, Jiang W, Zhang K, Cheng S. Crosstalk of dynamic functional modules in lung development of rhesus macaques. Mol Biosyst. 2016 Apr 22;12(4):1342-9. doi: 10.1039/c5mb00881f.

14 Xu J*, Feng L*, Han Z*, Li Y*, Wu A, Shao T, Ding N, Li L, Deng W, Di X, Wang J, Zhang L, Li X, Zhang K, Cheng S. Extensive ceRNA-ceRNA interaction networks mediated by miRNAs regulate development in multiple rhesus tissues. Nucleic Acids Res. 2016 Jun 30. pii: gkw587.

15 Zhang C, Kuang M, Li M, Feng L, Zhang K, Cheng S. SMC4, which is essentially involved in lung development, is associated with lung adenocarcinoma progression. Sci Rep. 2016 Sep 30;6:34508.

16 Yang X, Li J, Li X, Liang Z, Gao W, Liang J, Cheng S, Lin Y. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. J Nucl Med. 2017 Feb;58(2):258-265.

17 Shi L, Zhang Y, Feng L, Wang L, Rong W, Wu F, Wu J, Zhang K, Cheng S. Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma. Oncotarget. 2017 May 23;8(21):34844-34857.

18 Guo H, Zeng W, Feng L, Yu X, Li P, Zhang K, Zhou Z, Cheng S. Integrated transcriptomic analysis of distance-related field cancerization in rectal cancer patients. Oncotarget. 2017 May 15. doi: 10.18632/oncotarget.17864.

19 Kuang M*, Cheng J*, Zhang C*, Feng L*, Xu X, Zhang Y, Zu M, Cui J, Yu H, Zhang K, Yang A, Cheng S. A novel signature for stratifying the molecular heterogeneity of the tissue-infiltrating T-cell receptor repertoire reflects gastric cancer prognosis. Sci Rep. 2017 Aug 10;7(1):7762. doi: 10.1038/s41598-017-08289-z.

20 Zhang B, Feng L, Guo H, Li H, Wang Y, Zhang K, Yu X, Cheng S. Villi-specific Gene Expression Reveals Novel Prognostic Biomarkers in Multiple Human Cancers. J Cancer. 2017 Aug 23; 8(14):2793-2801. doi: 10.7150/jca.19787. eCollection 2017.

21 Feng L, Qian H, Yu X, Liu K, Xiao T, Zhang C, Kuang M, Cheng S, Li X, Wan J, Zhang K. Heterogeneity of tumor-infiltrating lymphocytes ascribed to local immune status rather than neoantigens by multi-omics analysis of glioblastoma multiforme. Sci Rep. 2017 Jul 31;7(1):6968. doi: 10.1038/s41598-017-05538-z. ^[1]